Nivolumab

Drugs of Today

Volumn 50, Issue 12, 2014, Pages 791-802

  Fulchiero, E ^a   Jimeno, A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Melanoma; Nivolumab; Targeted therapy

Indexed keywords

ASPARTATE AMINOTRANSFERASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; C REACTIVE PROTEIN; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DOCETAXEL; ERLOTINIB; EVEROLIMUS; GAMMA GUANOSINE TRIPHOSPHATE; GEMCITABINE; GUANOSINE TRIPHOSPHATE; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; LIOTHYRONINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NIVOLUMAB; PACLITAXEL; PAZOPANIB; PEMETREXED; PROGRAMMED DEATH 1 RECEPTOR; SUNITINIB; THYROXINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CASTRATION RESISTANT PROSTATE CANCER; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TOLERABILITY; ENDOCRINE DISEASE; FATIGUE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HEPATITIS; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SKIN DISEASE; SOLID TUMOR; CLINICAL TRIAL (TOPIC); NEOPLASM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MELANOMA; NEOPLASMS;

EID: 84919965065     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.12.2235103     Document Type: Review

References (55)

1. Atallah, E., Flaherty, L. Treatment of metastatic malignant melanoma. Curr Treat options oncol 2005, 6(3): 185-93.
2. Serrone, L., Zeuli, M., Sega, F.M., Cognetti, F. Dacarbazinebased chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer res 2000, 19(1): 21-34.
3. Lens, M.B., Dawes, M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. br J Dermatol 2004, 150(2): 179-85.
4. Eggermont, A.M., Robert, C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011, 47(14): 2150-7.
5. Bhatia, S., Tykodi, S.S., Thompson, J.A. Treatment of metastatic melanoma: an overview. oncology (Williston park) 2009, 23(6): 488-96.
6. Agarwala, S.S. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009, 9(5): 587-95.
7. Atkins, M.B., Kunkel, L., Sznol, M., Rosenberg, S.A. Highdose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci am 2000, 6(Suppl. 1): S11-4.
8. Phan, G.Q., Attia, P., Steinberg, S.M., White, D.E., Rosenberg, S.A. Factors associated with response to highdose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001, 19(15): 3477-82.
9. Rosenberg, S.A., Yang, J.C., Topalian, S.L. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JaMa 1994, 271(12): 907-13.
10. Raaijmakers, M.I., Rozati, S., Goldinger, S.M., Widmer, D.S., Dummer, R., Levesque, M.P. Melanoma immunotherapy: historical Precedents, recent successes and future prospects. immunotherapy 2013, 5(2): 169-82.
11. Steiner, A., Wolf, C., Pehamberger, H. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN Alpha, r-IFN Gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol 1987, 113(5): 459-65.
12. Chapman, P.B., Hauschild, A., Robert, C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26): 2507-16.
13. Sosman, J.A., Kim, K.B., Schuchter, L. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8): 707-14.
14. Gray-Schopfer, V., Wellbrock, C., Marais, R. Melanoma biology and new targeted therapy. nature 2007, 445(7130): 851-7.
15. Naidoo, J., Page, D.B., Wolchok, J.D. Immune checkpoint blockade. hematol oncol Clin North Am 2014, 28(3): 585-600.
16. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. nat Rev Cancer 2012, 12(4): 252-64.
17. Harvey, R.D. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther 2014, 96(2): 214-23.
18. Hodi, F.S., o'Day, S.J., McDermott, D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8): 711-23.
19. Robert, C., Thomas, L., Bondarenko, I. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26): 2517-26.
20. Topalian, S.L., Drake, C.G., Pardoll, D.M. Targeting the PD- 1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr opin immunol 2012, 24(2): 207-12.
21. Brahmer, J.R., Drake, C.G., Wollner, I. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical Activity, Pharmacodynamics, and immunologic correlates. J Clin oncol 2010, 28(19): 3167-75.
22. Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. annu rev immunol 2008, 26: 677-704.
23. Freeman, G.J., Long, A.J., Iwai, Y. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192(7): 1027-34.
24. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. proc natl acad Sci u S a 2002, 99(19): 12293-7.
25. McDermott, D.F., Atkins, M.B. PD-1 as a potential target in cancer therapy. Cancer Med 2013, 2(5): 662-73.
26. Sierro, S.R., Donda, A., Perret, R., Guillaume, P., Yagita, H., Levy, F., Romero, P. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J immunol 2011, 41(8): 2217-28.
27. Mkrtichyan, M., Najjar, Y.G., Raulfs, E.C. et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J immunol 2011, 41(10): 2977-86.
28. Weber, J.S., Kudchadkar, R.R., Yu, B. et al. Safety, Efficacy, and biomarkers of nivolumab with vaccine in ipilimumabrefractory or -naive melanoma. J Clin oncol 2013, 31(34): 4311-8.
29. ONO files for regulatory approval of "nivolumab (ONO- 4538/BMS-936558)" for treatment of malignant melanoma [news release]. ono pharmaceutical Co., ltd., December 23, 2013.
30. Blank, C., Kuball, J., Voelkl, S. et al. Blockade of PD-L1 (B7- H1) augments human tumor-specific T cell responses in vitro. int J Cancer 2006, 119(2): 317-27.
31. Wong, R.M., Scotland, R.R., Lau, R.L., Wang, C., Korman, A.J., Kast, W.M., Weber, J.S. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. int immunol 2007, 19(10): 1223-34.
32. Iwai, Y., Terawaki, S., Honjo, T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. int immunol 2005, 17(2): 133-44.
33. Okudaira, K., Hokari, R., Tsuzuki, Y. et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. int J oncol 2009, 35(4): 741-9.
34. Wang, C., Thudium, K.B., Han, M. et al. In vitro characterization of the anti-PD-1 antibody Nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer immunol res 2014, 2(9): 846-56.
35. Selby, M., Engelhardt, J., Lu, L.-S., Quigley, M., Wang, C., Chen, B., Korman, A.J. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. 49th annu Meet am Soc Clin oncol (aSCo) (May 31-June 4, Chicago) 2013, Abst 3061.
36. Haley, P.J. Species differences in the structure and function of the immune system. Toxicology 2003, 188(1): 49-71.
37. Mestas, J., Hughes, C.C. Of mice and not men: differences between mouse and human immunology. J immunol 2004, 172(5): 2731-8.
38. Liu, J., Blake, S.J., Smyth, M.J., Teng, M.W.L. Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Trans immunol 2014, 3: e22.
39. Topalian, S.L., Hodi, F.S., Brahmer, J.R. et al. Safety, Activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26): 2443-54.
40. Agrawal, S., Feng, Y., Kollia, G. et al. Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody. 48th annu Meet am Soc Clin oncol (aSCo) (June 1-5, Chicago) 2012, Abst TpS2622.
41. Wolchok, J.D., Kluger, H., Callahan, M.K. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2): 122-33.
42. Lipson, E.J. Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti- PD1 antibodies. oncoimmunology 2013, 2(4): e23661.
43. Hodi, F.S., Sznol, M., Kluger, H.M. et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. 50th annu Meet am Soc Clin oncol (aSCo) (May 30-June 3, Chicago) 2014, Abst 9002.
44. Topalian, S.L., Sznol, M., McDermott, D.F. et al. Survival, durable tumor Remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin oncol 2014, 32(10): 1020-30.
45. Kluger, H., Sznol, M., Callahan, M.K. et al. Survival, response Duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO- 4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). 39th Eur Soc Med oncol (ESMo) Congr (September 26-30, Madrid) 2014, Abst 1085o.
46. Yamazaki, N., Tahara, H., Uhara, H., Moroi, Y., Kiyohara, Y. Phase 2 study of nivolumab (anti-PD-1; ONO-4538/BMS- 936558) in patients with advanced melanoma. Eur Cancer Congr (September 27-october 1, amsterdam) 2013, Abst 3738.
47. Weber, J.S., Minor, D.R., D'angelo, S. et al. A phase 3 Randomized, open-label study of nivolumab (anti-PD-1; BMS- 936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. 39th Eur Soc Med oncol (ESMo) Congr (September 26-30, Madrid) 2014, Abst lba3.
48. Gangadhar, T.C., Vonderheide, R.H. Mitigating the toxic effects of anticancer immunotherapy. nat rev Clin oncol 2014, 11(2): 91-9.
49. Dewan, M.Z., Galloway, A.E., Kawashima, N., Dewyngaert, J.K., Babb, J.S., Formenti, S.C., Demaria, S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer res 2009, 15(17): 5379-88.
50. Lu, J., lee-gabel, L., Nadeau, M.C., Ferencz, T.M., Soefje, S.A. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J oncol pharm pract 2014, advanced publication.
51. Robert, C., Ribas, A., Wolchok, J.D. et al. Anti-programmeddeath- receptor-1 treatment with pembrolizumab in ipilimumab- refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. lancet 2014, 384(9948): 1109-17.
52. Hamid, O., Sosman, J.A., Lawrence, D. et al. Clinical Activity, Safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). 49th annu Meet am Soc Clin oncol (aSCo) (May 31-June 4, Chicago) 2013, Abst 9010.
53. Sosman, J.A., Hamid, O., Lawrence, D. et al. A study of MPDL3280A (engineered anti-PDL1): Activity, safety and characterization of immune response in pre- and on-treatment tumors in metastatic melanoma (mM) pts. Soc Melanoma res 2013 Congr (november 17-20, philadelphia) 2013, abst.
54. Herbst, R.S., Gordon, M.S., Fine, G.F. et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. 49th annu Meet am Soc Clin oncol (aSCo) (May 31-June 4, Chicago) 2013, Abst 3000.
55. Robert, C., Long, G.V., Brady, B. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2014, advanced publication.